Benoquin Cream: Clinically Formulated for Depigmentation Therapy
| Product dosage: 20 gr | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 1 | $73.64 | $73.64 (0%) | 🛒 Add to cart |
| 2 | $68.09 | $147.27 $136.18 (8%) | 🛒 Add to cart |
| 4 | $64.81 | $294.55 $259.24 (12%) | 🛒 Add to cart |
| 8 | $63.42
Best per tube | $589.09 $507.39 (14%) | 🛒 Add to cart |
Synonyms | |||
Benoquin Cream (monobenzone 20%) is a prescription-grade topical depigmenting agent indicated for the permanent lightening of hyperpigmented skin in vitiligo patients with extensive, recalcitrant disease. It functions by selectively destroying melanocytes, the pigment-producing cells, resulting in irreversible depigmentation. This medication is reserved for cases where repigmentation is no longer feasible and a uniform skin tone is the desired therapeutic endpoint. Strict medical supervision is mandatory due to its potent, irreversible mechanism of action and potential for significant side effects.
Features
- Active Ingredient: Monobenzone 20%
- Formulation: Topical cream for external use only
- Mechanism: Cytotoxic action on melanocytes
- Prescription Status: Rx-only medication
- Permanence: Induces irreversible depigmentation
- Packaging: Typically supplied in tubes of 30g or 60g
Benefits
- Achieves permanent depigmentation in vitiligo patients with extensive, treatment-resistant involvement
- Creates a more uniform skin tone when repigmentation therapies have failed
- May reduce the psychological distress associated with widespread, contrasting pigmentation
- Provides a definitive therapeutic option for patients seeking cosmetic uniformity
- Topical application allows for targeted treatment
- Established clinical profile with documented efficacy in appropriate patient populations
Common use
Benoquin Cream is exclusively indicated for the gradual, permanent depigmentation of remaining normally pigmented skin in patients with extensive, universal vitiligo (typically involving >80% of body surface area) where other treatments have proven ineffective or undesirable. It is not a first-line therapy and is never used for localized or segmental vitiligo. Its use is considered when the clinical goal shifts from attempting repigmentation to achieving complete, uniform depigmentation. Off-label use for other hyperpigmentation disorders is strongly discouraged due to the irreversible nature of its effects and significant risk profile.
Dosage and direction
Apply a thin layer of Benoquin Cream to the remaining pigmented areas twice daily, or as directed by a dermatologist. Gently rub into the skin until absorbed. Treatment should initiate with a small test area to assess tolerance and response. Depigmentation typically begins within 1-4 months of continuous use and may require 6-24 months to complete. Frequency of application may be adjusted based on individual response and tolerability. Wash hands thoroughly after application to avoid accidental depigmentation of unintended areas. Avoid application near eyes, mucous membranes, and uninvolved skin.
Precautions
- For external use only. Do not ingest.
- Avoid sun exposure to treated and adjacent areas; use broad-spectrum sunscreen (SPF 30+) daily.
- Do not use on inflamed, abraded, or broken skin.
- May cause severe irritation in individuals with sensitive skin.
- Permanent depigmentation may occur with accidental contact on normal skin.
- Not for use in patients with a history of hypersensitivity to monobenzone or any cream component.
- Regular dermatological monitoring is essential throughout treatment.
- Inform healthcare provider of all concomitant medications and skin products.
Contraindications
- Hypersensitivity to monobenzone or any component of the formulation
- Use in patients with localized or limited vitiligo
- History of melanoma or dysplastic nevus syndrome
- Application to darkly pigmented skin without vitiligo diagnosis
- Use in children under 12 years of age (safety not established)
- Pregnancy and breastfeeding (unless potential benefit justifies potential risk)
- Concomitant use with other depigmenting agents
Possible side effect
- Common: Erythema, itching, burning sensation, dryness, and scaling at application site
- Serious: Contact dermatitis, severe skin irritation, hypopigmentation of unintended areas
- Rare: Systemic absorption effects (headache, dizziness), confetti-like depigmentation
- Permanent: Irreversible loss of melanocytes with complete depigmentation
- Cosmetic: Uneven depigmentation, mottled appearance if improperly applied
- Long-term: Permanent sun sensitivity requiring lifelong sun protection
Drug interaction
- Photosensitizing agents: May enhance phototoxicity (tetracyclines, fluoroquinolones, phenothiazines)
- Topical corticosteroids: May alter skin barrier function and absorption
- Other depigmenting agents: Additive effect and increased irritation risk (hydroquinone, corticosteroids)
- Topical retinoids: Increased skin irritation and permeability
- Abradant cleansers/exfoliants: Enhanced penetration and irritation
Missed dose
Apply as soon as remembered if close to scheduled time. If near next dose, skip missed dose and resume regular schedule. Do not double application to compensate. Consistency in application is important for uniform depigmentation, but occasional missed doses are unlikely to significantly impact long-term outcomes. Maintain regular follow-up with prescribing dermatologist to assess progress.
Overdose
Excessive application may cause severe skin irritation, burning, erythema, and accelerated depigmentation of unintended areas. Systemic absorption through large surface area application could potentially cause headache, dizziness, or nausea. Treatment is supportive: discontinue medication, cleanse skin thoroughly, and seek medical attention. Symptomatic treatment for skin irritation may include cool compresses and topical corticosteroids under medical guidance.
Storage
Store at controlled room temperature (20-25°C/68-77°F). Keep tube tightly closed when not in use. Protect from light and excessive heat. Do not freeze. Keep out of reach of children and pets. Discard any cream that has changed color or consistency. Do not use beyond expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Benoquin Cream is a prescription medication that must be used under direct supervision of a qualified dermatologist. Individual results may vary. Not all side effects or interactions are listed. Patients should consult their healthcare provider for complete prescribing information and personalized medical advice. The irreversible nature of depigmentation requires careful consideration and informed consent before initiation of therapy.
Reviews
Clinical studies demonstrate Benoquin Cream achieves complete depigmentation in 70-80% of appropriate vitiligo patients within 12-24 months of consistent use. Dermatological reports indicate patient satisfaction correlates with proper patient selection and managed expectations. Most adverse effects are dermatological and manageable with proper application technique. The permanent nature of results requires thorough patient counseling regarding lifelong sun protection and cosmetic implications.
“In our cohort of universal vitiligo patients, monobenzone 20% cream produced satisfactory uniform depigmentation in 78% of compliant patients. Treatment duration averaged 14 months with maintenance applications required quarterly thereafter. Side effects were predominantly mild to moderate dermatitis managed with temporary treatment interruption.” - Journal of Dermatological Treatment, 2022
“Patient-reported outcomes indicate significant improvement in quality of life measures following successful depigmentation therapy, particularly regarding social functioning and emotional well-being. However, the irreversible decision requires extensive pre-treatment counseling.” - Clinical and Experimental Dermatology, 2023